Trial Profile
A Prospective Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Gimeracil/oteracil/tegafur
- Indications Cancer metastases; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 14 Jan 2018 Status changed from not yet recruiting to recruiting.
- 31 Oct 2017 New trial record